CXCL10 Binding Antibodies for Distinguishing Biologically Relevant Forms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing diagnostics struggle to accurately discriminate between different biologically relevant forms of CXCL10, limiting their application as biomarkers for human diseases.
Innovation Solution
Development of antibodies that bind specifically to full-length, N-terminally truncated, and citrullinated forms of CXCL10, allowing for the discrimination between benign and malignant conditions by measuring the ratio of these forms in combination with other biological markers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If commercially available diagnostics are used to detect CXCL10, then the detection process is simple, but the ability to discriminate between different biologically relevant forms of CXCL10 is poor
Solution Approach 1:
The invention segments the detection capability by developing separate antibody reagents that specifically target different forms of CXCL10 (full-length, N-terminally truncated, and citrullinated forms). This allows the detection system to distinguish between these forms by using multiple specific antibodies, thereby improving measurement precision without requiring a completely complex new detection platform.
Solution Approach 2:
The invention changes the detection parameter from generic CXCL10 detection to form-specific detection by modifying the antibody specificity. By using antibodies with different binding specificities (some binding full-length only, others binding truncated or citrullinated forms), the system can measure different parameters (form composition) of the same analyte, enabling discrimination between disease states.
2Adaptability or versatility
If single-specificity antibodies are used to detect CXCL10, then the antibody design is simple, but the ability to detect all biologically relevant forms is limited
Solution Approach 1:
The invention creates a universal detection system by developing a panel of antibodies where each antibody can detect specific forms of CXCL10. The antibodies are designed to work together in a coordinated manner, with some antibodies detecting full-length CXCL10, others detecting truncated forms, and others detecting citrullinated forms. This multi-functional panel allows comprehensive detection of all biologically relevant CXCL10 forms while maintaining relatively simple individual antibody designs.
3Reliability
If the ratio of different CXCL10 forms is measured, then discrimination between benign and malignant conditions improves, but the measurement process becomes more complex
Solution Approach 1:
The invention implements feedback by measuring the ratio of different CXCL10 forms (full-length to truncated and citrullinated forms) and using this ratio information to discriminate between benign and malignant conditions. The system provides feedback about the functional state of CXCL10 in the sample, where a higher ratio of inactive forms (truncated and citrullinated) relative to active full-length form indicates malignant conditions. This feedback mechanism improves diagnostic reliability by providing contextual information about protein functionality.
Data Source
AI summary
The present invention relates to C-X-C motif chemokine ligand 10 (CXCL10) binding proteins and uses thereof. The present invention also relates to methods of detecting and/or diagnosing a condition in a subject, comprising determining a level of CXCL10 in the subject.